Botanix Pharmaceuticals Ltd
ASX:BOT

Watchlist Manager
Botanix Pharmaceuticals Ltd Logo
Botanix Pharmaceuticals Ltd
ASX:BOT
Watchlist
Price: 0.32 AUD 1.59% Market Closed
Market Cap: 581.6m AUD
Have any thoughts about
Botanix Pharmaceuticals Ltd?
Write Note

Intrinsic Value

The intrinsic value of one BOT stock under the Base Case scenario is 1.73 AUD. Compared to the current market price of 0.32 AUD, Botanix Pharmaceuticals Ltd is Undervalued by 82%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

BOT Intrinsic Value
1.73 AUD
Undervaluation 82%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Botanix Pharmaceuticals Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for BOT cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about BOT?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Botanix Pharmaceuticals Ltd

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Botanix Pharmaceuticals Ltd

Provide an overview of the primary business activities
of Botanix Pharmaceuticals Ltd.

What unique competitive advantages
does Botanix Pharmaceuticals Ltd hold over its rivals?

What risks and challenges
does Botanix Pharmaceuticals Ltd face in the near future?

Has there been any significant insider trading activity
in Botanix Pharmaceuticals Ltd recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Botanix Pharmaceuticals Ltd.

Provide P/S
for Botanix Pharmaceuticals Ltd.

Provide P/E
for Botanix Pharmaceuticals Ltd.

Provide P/OCF
for Botanix Pharmaceuticals Ltd.

Provide P/FCFE
for Botanix Pharmaceuticals Ltd.

Provide P/B
for Botanix Pharmaceuticals Ltd.

Provide EV/S
for Botanix Pharmaceuticals Ltd.

Provide EV/GP
for Botanix Pharmaceuticals Ltd.

Provide EV/EBITDA
for Botanix Pharmaceuticals Ltd.

Provide EV/EBIT
for Botanix Pharmaceuticals Ltd.

Provide EV/OCF
for Botanix Pharmaceuticals Ltd.

Provide EV/FCFF
for Botanix Pharmaceuticals Ltd.

Provide EV/IC
for Botanix Pharmaceuticals Ltd.

Show me price targets
for Botanix Pharmaceuticals Ltd made by professional analysts.

What are the Revenue projections
for Botanix Pharmaceuticals Ltd?

How accurate were the past Revenue estimates
for Botanix Pharmaceuticals Ltd?

What are the Net Income projections
for Botanix Pharmaceuticals Ltd?

How accurate were the past Net Income estimates
for Botanix Pharmaceuticals Ltd?

What are the EPS projections
for Botanix Pharmaceuticals Ltd?

How accurate were the past EPS estimates
for Botanix Pharmaceuticals Ltd?

What are the EBIT projections
for Botanix Pharmaceuticals Ltd?

How accurate were the past EBIT estimates
for Botanix Pharmaceuticals Ltd?

Compare the revenue forecasts
for Botanix Pharmaceuticals Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Botanix Pharmaceuticals Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Botanix Pharmaceuticals Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Botanix Pharmaceuticals Ltd compared to its peers.

Compare the P/E ratios
of Botanix Pharmaceuticals Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing Botanix Pharmaceuticals Ltd with its peers.

Analyze the financial leverage
of Botanix Pharmaceuticals Ltd compared to its main competitors.

Show all profitability ratios
for Botanix Pharmaceuticals Ltd.

Provide ROE
for Botanix Pharmaceuticals Ltd.

Provide ROA
for Botanix Pharmaceuticals Ltd.

Provide ROIC
for Botanix Pharmaceuticals Ltd.

Provide ROCE
for Botanix Pharmaceuticals Ltd.

Provide Gross Margin
for Botanix Pharmaceuticals Ltd.

Provide Operating Margin
for Botanix Pharmaceuticals Ltd.

Provide Net Margin
for Botanix Pharmaceuticals Ltd.

Provide FCF Margin
for Botanix Pharmaceuticals Ltd.

Show all solvency ratios
for Botanix Pharmaceuticals Ltd.

Provide D/E Ratio
for Botanix Pharmaceuticals Ltd.

Provide D/A Ratio
for Botanix Pharmaceuticals Ltd.

Provide Interest Coverage Ratio
for Botanix Pharmaceuticals Ltd.

Provide Altman Z-Score Ratio
for Botanix Pharmaceuticals Ltd.

Provide Quick Ratio
for Botanix Pharmaceuticals Ltd.

Provide Current Ratio
for Botanix Pharmaceuticals Ltd.

Provide Cash Ratio
for Botanix Pharmaceuticals Ltd.

What is the historical Revenue growth
over the last 5 years for Botanix Pharmaceuticals Ltd?

What is the historical Net Income growth
over the last 5 years for Botanix Pharmaceuticals Ltd?

What is the current Free Cash Flow
of Botanix Pharmaceuticals Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for Botanix Pharmaceuticals Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Botanix Pharmaceuticals Ltd

Current Assets 82.9m
Cash & Short-Term Investments 79.3m
Receivables 2.3m
Other Current Assets 1.3m
Non-Current Assets 29.6m
PP&E 71.8k
Intangibles 29.5m
Current Liabilities 3.7m
Accounts Payable 3.6m
Other Current Liabilities 107.5k
Efficiency

Earnings Waterfall
Botanix Pharmaceuticals Ltd

Revenue
677.5k AUD
Operating Expenses
-12.8m AUD
Operating Income
-12.1m AUD
Other Expenses
-1.8m AUD
Net Income
-13.9m AUD

Free Cash Flow Analysis
Botanix Pharmaceuticals Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

BOT Profitability Score
Profitability Due Diligence

Botanix Pharmaceuticals Ltd's profitability score is 42/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROIC
Exceptional 3-Years Revenue Growth
Exceptional Revenue Growth Forecast
Exceptional 1-Year Revenue Growth
42/100
Profitability
Score

Botanix Pharmaceuticals Ltd's profitability score is 42/100. The higher the profitability score, the more profitable the company is.

BOT Solvency Score
Solvency Due Diligence

Botanix Pharmaceuticals Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Botanix Pharmaceuticals Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BOT Price Targets Summary
Botanix Pharmaceuticals Ltd

Wall Street analysts forecast BOT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BOT is 0.66 AUD with a low forecast of 0.66 AUD and a high forecast of 0.68 AUD.

Lowest
Price Target
0.66 AUD
105% Upside
Average
Price Target
0.66 AUD
107% Upside
Highest
Price Target
0.68 AUD
113% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for BOT?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for BOT is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

BOT Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Botanix Pharmaceuticals Ltd Logo
Botanix Pharmaceuticals Ltd

Country

Australia

Industry

Pharmaceuticals

Market Cap

579.2m AUD

Dividend Yield

0%

Description

Botanix Pharmaceuticals Ltd. engages in the development of therapeutics for the treatment of skin diseases. The company is headquartered in Perth, Western Australia. The firm's product pipelines are based on drug delivery technology known as Permetrex. Its product pipeline consists of three clinical programs, which are using synthetic cannabidiol in the topical treatment of serious skin diseases and for antimicrobial applications. Its product pipeline includes BTX 1503 Gel, BTX 1702 Solution and BTX 1801 Ointment. Its BTX1503 Gel is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. Its BTX 1702 Solution is used for the treatment of papulopustular rosacea. Its BTX 1801 Ointment is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus (MRSA). The firm also has a chemistry program to identify, synthesize and test chemical entities that are related to naturally occurring cannabinoids.

Contact

WESTERN AUSTRALIA
Perth
Level 1, 50 Angove Street, North Perth
+61865552945.0
www.botanixpharma.com

IPO

1985-01-24

Employees

-

Officers

MD & Executive Chairman
Mr. Vincent P. Ippolito
Chief Executive Officer
Dr. Howie McKibbon
Chief Financial Officer
Mr. Graeme Morissey
Executive Director
Mr. Matthew Callahan L.L.B., M.B.A., MBA LLB
Senior Vice President of Pharmaceutical Development
Dr. Jack Hoblitzell Ph.D.
Chief Medical Adviser
Dr. Patricia S. Walker M.D., Ph.D.
Show More
Chief Business Officer
Dr. Boris Meyerson Ph.D.
Head of Corporate Affairs
Mr. David Morgan
Head of HCP Marketing & Sales Training
Mr. Kevin Wojciechowski
Director of Sales Operations
Mr. Darin Van Arsdale
Show Less

See Also

Discover More
What is the Intrinsic Value of one BOT stock?

The intrinsic value of one BOT stock under the Base Case scenario is 1.73 AUD.

Is BOT stock undervalued or overvalued?

Compared to the current market price of 0.32 AUD, Botanix Pharmaceuticals Ltd is Undervalued by 82%.

Back to Top